Janoschka C, Lindner M, Koppers N, Starost L, et al. Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound. Proc Natl Acad Sci U S A 2023;120:e2209944120.
PMID: 36574650